FundingWatcher
Home / Startups / By venture fund / RA Capital Management portfolio companies

RA Capital Management portfolio companies

Updated 16 Nov 2026

http://www.racap.com

RA Capital Management portfolio companies
One-time CSV
  • 47 funded companies, 46 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-ra-capital-management.csv47 rows × 18 columns
CompanyCityLast roundAmountDate
Element BiosciencesSan DiegoSeries E$277.0M2026-06-09
GametoNew YorkSeries C$44.0M2025-08-12
Claris BiotherapeuticsJersey CitySeries B$118.0M2026-07-28
ADCendoCopenhagenSeries C$75.0M2026-04-14
Terrestrial BioCambridgeSeries C$50.0M2026-03-26
Capstan TherapeuticsSan DiegoSeries B$175.0M2024-03-20
Superluminal MedicinesBostonSeries B$65.5M2026-09-03
Alchemab TherapeuticsLondonSeries A$33.6M2026-07-09

8 rows of the CSV in 5 of its 18 columns.

47
Startups
$9.9B
Total raised
9
Funded in the last 12 months
$1.1B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 47
30 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston, United States Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
Superluminal Medicines Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. Artificial intelligence Boston, United States Series B $65.5M 2026-09-03 $223.5M Insight Partners, RA Capital Management, NVentures 11 to 50 2022
Claris Biotherapeutics Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. Biotech Jersey City, United States Series B $118.0M 2026-07-28 $225.1M RA Capital Management, Novo Holdings, Janus Henderson Investors +1 1 to 10 2018
Alchemab Therapeutics Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. Biotech London, United Kingdom Series A $33.6M 2026-07-09 $151.1M DCVC, RA Capital Management, DHVC +2 51 to 100 2019
Element Biosciences Unicorn Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. Biotech San Diego, United States Series E $277.0M 2026-06-09 $678.0M RA Capital Management, Fidelity, Wellington Management +2 251 to 500 2017
CellCentric CellCentric develops small molecule therapies for treating cancer and multiple myeloma. Biotech Cambridge, United Kingdom Series D $220.0M 2026-05-06 $475.7M Innovate UK, 5Y Capital, RA Capital Management +2 11 to 50 2003
ADCendo ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. Biotech Copenhagen, Denmark Series C $75.0M 2026-04-14 $324.6M RA Capital Management, Novo Holdings, Gilde Healthcare +2 51 to 100 2017
Terrestrial Bio Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. Biotech Cambridge, United States Series C $50.0M 2026-03-26 $180.9M RA Capital Management, National Institutes of Health, The Engine 11 to 50 2012
Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown, United States Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
Adcytherix Adcytherix is a biopharmaceutical firm developing antibody drug conjugates. Biotech Marseille, France Series A $122.8M 2025-10-16 $155.1M RA Capital Management, Pureos Bioventures, Pontifax +1 11 to 50 2023
TORL BioTherapeutics TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. Biotech Culver City, United States Series C $96.0M 2025-10-07 $412.0M Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 51 to 100 2018
Gameto Gameto develops cell-engineered therapeutics for the female reproductive system. Biotech New York, United States Series C $44.0M 2025-08-12 $117.0M FJ Labs, Insight Partners, Gaingels +2 11 to 50 2020
Verdiva Bio Verdiva Bio develops treatments for patients with obesity and cardiometabolic diseases. Biotech London, United Kingdom Series A $411.0M 2025-01-09 $411.0M General Atlantic, RA Capital Management, OrbiMed +1 11 to 50 2024
Alentis Therapeutics Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. Biotech Allschwil, Switzerland Series D $181.4M 2024-11-12 Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 51 to 100 2019
Trace Neuroscience Trace Neuroscience aims to extend the promise of genetic medicine to patients. Biotech South San Francisco, United States Series A $101.0M 2024-11-12 $101.0M RA Capital Management, Atlas Venture, Third Rock Ventures 11 to 50 2024
Convergent Therapeutics Convergent Therapeutics develops radiopharmaceutical therapies for prostate cancer. Health care Cambridge, United States Series A $40.0M 2024-09-24 $130.0M RA Capital Management, OrbiMed, Invus 1 to 10 2021
Halda Therapeutics Halda Therapeutics is a research-stage drug discovery company. Biotech New Haven, United States Series B $126.0M 2024-08-12 $208.3M Canaan Partners, RA Capital Management, Connecticut Innovations +2 11 to 50 2018
MBX Biosciences MBX Biosciences is a preclinical biotech company creating therapies for rare endocrine diseases. Biotech Carmel, United States Series C $63.5M 2024-08-05 $238.4M New Enterprise Associates, RA Capital Management, OrbiMed +2 11 to 50 2019
AltruBio AltruBio develops targeted antibody therapeutics for cancer and immune-related inflammatory diseases. Biotech Los Altos, United States Series B $225.0M 2024-05-21 $327.6M RA Capital Management, Blackstone, Cormorant Asset Management +2 11 to 50 2000
Bluejay Therapeutics Bluejay Therapeutics is a private biopharmaceutical company developing cures for infectious diseases. Biotech San Mateo, United States Series C $182.0M 2024-05-09 $242.2M RA Capital Management, Wellington Management, Novo Holdings +2 11 to 50 2019
Capstan Therapeutics Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. Biotech San Diego, United States Series B $175.0M 2024-03-20 $340.0M RA Capital Management, OrbiMed, Alexandria Venture Investments +2 101 to 250 2021
Sionna Therapeutics Sionna Therapeutics develops small molecule therapies for treating cystic fibrosis. Biotech Natick, United States Series C $182.0M 2024-03-06 $292.0M RA Capital Management, OrbiMed, T. Rowe Price +2 11 to 50 2018
Aiolos Bio Aiolos Bio is a biotech company developing therapies for respiratory diseases and immune conditions. Biotech San Francisco, United States Series A $245.0M 2023-10-24 $245.0M RA Capital Management, Atlas Venture, Forbion Capital Partners +2 11 to 50 2023
Rampart Bioscience Rampart Bioscience develops gene medicines for long-lasting treatment of diverse diseases. Biotech La Jolla, United States Series A $85.0M 2023-10-24 $85.0M RA Capital Management, OrbiMed, Forbion Capital Partners +1 11 to 50 2019
Hyku Hyku develops covalent drugs that precisely target disease-causing proteins. Biotech Lexington, United States Seed $56.0M 2023-09-19 $56.0M KB Investment, RA Capital Management, Novartis Venture Fund +2 11 to 50 2021
Mariana Oncology Mariana Oncology conducts biotechnology research in the oncology field. Biotech Watertown, United States Series B $175.0M 2023-09-07 $250.0M RA Capital Management, Forbion Capital Partners, Surveyor Capital +1 11 to 50 2021
Metagenomi Metagenomi uses metagenomics and machine learning to discover genome editing systems for therapeutics. Artificial intelligence Emeryville, United States Series B $100.0M 2023-01-05 $466.7M RA Capital Management, Bristol-Myers Squibb, Marshall Wace +1 101 to 250 2018
Empatica Empatica develops affective computing technology and human data analytics. Artificial intelligence Cambridge, United States Series B $25.9M 2022-08-02 $35.6M Bossa Invest, Endeavor Catalyst, RA Capital Management +2 101 to 250 2011
CDR-Life AG CDR-Life AG develops therapeutic antibody fragments for immuno-oncology. Biotech Schlieren, Switzerland Series A $76.0M 2022-04-13 $76.0M RA Capital Management, Omega Funds, Jeito Capital 51 to 100 2017
Synthego Synthego provides genome engineering services and CRISPR tools for life science research. Artificial intelligence Redwood City, United States Series E $200.0M 2022-02-17 $459.7M Intel Capital, Founders Fund, Menlo Ventures +2 101 to 250 2012

Table 1. RA Capital Management portfolio companies: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 47.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 Element Biosciences Unicorn Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. Biotech San Diego, United States Series E $277.0M 2026-06-09 $678.0M RA Capital Management, Fidelity, Wellington Management +2 251 to 500 2017
2 CellCentric CellCentric develops small molecule therapies for treating cancer and multiple myeloma. Biotech Cambridge, United Kingdom Series D $220.0M 2026-05-06 $475.7M Innovate UK, 5Y Capital, RA Capital Management +2 11 to 50 2003
3 Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown, United States Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
4 Claris Biotherapeutics Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. Biotech Jersey City, United States Series B $118.0M 2026-07-28 $225.1M RA Capital Management, Novo Holdings, Janus Henderson Investors +1 1 to 10 2018
5 Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston, United States Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
6 ADCendo ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. Biotech Copenhagen, Denmark Series C $75.0M 2026-04-14 $324.6M RA Capital Management, Novo Holdings, Gilde Healthcare +2 51 to 100 2017
7 Superluminal Medicines Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. Artificial intelligence Boston, United States Series B $65.5M 2026-09-03 $223.5M Insight Partners, RA Capital Management, NVentures 11 to 50 2022
8 Terrestrial Bio Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. Biotech Cambridge, United States Series C $50.0M 2026-03-26 $180.9M RA Capital Management, National Institutes of Health, The Engine 11 to 50 2012
9 Alchemab Therapeutics Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. Biotech London, United Kingdom Series A $33.6M 2026-07-09 $151.1M DCVC, RA Capital Management, DHVC +2 51 to 100 2019

Table 2. RA Capital Management portfolio companies: the 9 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 OrbiMed Private equity firm New York, United States 10 21%
2 T. Rowe Price Private equity firm Baltimore, United States 6 13% 1 Element Biosciences
3 Wellington Management Private equity firm Boston, United States 5 11% 1 Element Biosciences
4 Bristol-Myers Squibb Venture capital firm New York, United States 5 11%
5 Fidelity Investment bank Boston, United States 4 9% 1 Element Biosciences
6 Novo Holdings Corporate venture arm Hellerup, Denmark 3 6% 2 Claris Biotherapeutics, ADCendo
7 Alexandria Venture Investments Venture capital firm Pasadena, United States 3 6%
8 Invus Private equity firm New York, United States 3 6%
9 Atlas Venture Venture capital firm Cambridge, United States 3 6% 1 Diagonal Therapeutics
10 Deep Track Capital Hedge fund Greenwich, United States 3 6%
11 Forbion Capital Partners Private equity firm Naarden, The Netherlands 3 6%
12 Insight Partners Private equity firm New York, United States 2 4% 1 Superluminal Medicines
13 Gaingels Syndicate Burlington, United States 2 4% 1 Delix Therapeutics
14 Pontifax Venture capital firm Herzliya, Israel 2 4% 1 ADCendo
15 HealthCap Venture capital firm Stockholm, Sweden 2 4% 1 ADCendo

Table 3. RA Capital Management portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 46 98% $9.9B
Biotech 42 89% $9.4B
Software 7 15% $1.8B
Artificial intelligence 6 13% $1.5B
Hardware 1 2% $35.6M

Table 4. RA Capital Management portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Seed 3 6% $10.0M
Series A 11 23% $85.0M
Series B 14 30% $125.0M
Series C 12 26% $90.0M
Series D+ 7 15% $200.0M

Table 5. RA Capital Management portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
United States 37 79%
United Kingdom 3 6%
Switzerland 3 6%
Germany 2 4%
Denmark 1 2%
France 1 2%

Table 6. RA Capital Management portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Cambridge 7 15%
San Francisco 4 9%
San Diego 2 4%
New York 2 4%
Boston 2 4%
London 2 4%
Watertown 2 4%
Redwood City 2 4%
Allschwil 2 4%
Seattle 2 4%
Jersey City 1 2%
Copenhagen 1 2%

Table 7. RA Capital Management portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 1 11% $100.0M
September 2026 1 11% $65.5M
July 2026 2 22% $151.6M
June 2026 1 11% $277.0M
May 2026 1 11% $220.0M
April 2026 1 11% $75.0M
March 2026 1 11% $50.0M
January 2026 1 11% $125.0M

Table 8. RA Capital Management portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 9 19% $1.1B
2025 5 11% $673.8M
2024 18 38% $2.1B
2023 9 19% $902.2M
2022 3 6% $301.9M
2021 3 6% $218.1M

Table 9. RA Capital Management portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 4 9%
2020 to 2022 12 26%
2015 to 2019 24 51%
2010 to 2014 4 9%
Before 2010 3 6%

Table 10. RA Capital Management portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 6 13%
11 to 50 22 47%
51 to 100 10 21%
101 to 250 8 17%
251 to 500 1 2%

Table 11. RA Capital Management portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many RA Capital Management portfolio companies are on the list?
47, in the file dated 16 November 2026. 9 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 47 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

RA Capital Management portfolio companies: 47 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 47 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/ra-capital-management/